MO
54
-3
MCK
62
-5
DRI
50
5
BLK
61
6
IFF
60
-6
PRGO
31
2
ALLE
46
-2
HPE
49
4
AMGN
41
3
CL
59
-3
LUV
71
10
NTAP
65
-2
ZTS
17
-2
ADBE
44
3
CAT
76
3
WU
41
3
MKC
42
-3
VMC
59
3
NWS
42
-2
WM
56
3
MO
54
-3
MCK
62
-5
DRI
50
5
BLK
61
6
IFF
60
-6
PRGO
31
2
ALLE
46
-2
HPE
49
4
AMGN
41
3
CL
59
-3
LUV
71
10
NTAP
65
-2
ZTS
17
-2
ADBE
44
3
CAT
76
3
WU
41
3
MKC
42
-3
VMC
59
3
NWS
42
-2
WM
56
3
Financhill
Back

Spyre Therapeutics, Inc. 10K Form

Buy
59

SYRE
Spyre Therapeutics, Inc.

Last Price:
$33.54
Seasonality Move:
1.04%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SYRE News And Ratings

See the #1 stock for the next 7 days that we like better than SYRE

SYRE Financial Statistics

Sales & Book Value

Annual Sales: $0
Cash Flow: $-37.1M
Price / Cash Flow: 0
Annual Sales: $7.48
Price / Book: 5.49

Profitability

EPS (TTM): -2.17800
Net Income (TTM): $-127.7M
Gross Margin: $0
Return on Equity: -28.51%
Return on Assets: -24.15%

Spyre Therapeutics, Inc. Earnings Forecast

Key Spyre Therapeutics, Inc. Financial Ratios

  • Per Share Earnings over the last 11 years have been positive in 6 years.

Spyre Therapeutics, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: SYRE
Website: spyre.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 10.9
Quick Ratio: 10.51

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

SYRE Technical Analysis vs Fundamental Analysis

Buy
59
Spyre Therapeutics, Inc. (SYRE) is a Buy

Is Spyre Therapeutics, Inc. a Buy or a Sell?